Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Apr 18;19(4):e0302251. doi: 10.1371/journal.pone.0302251

The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products

Jeremy Garb 1,#, Gil Amitai 1,#, Allen Lu 2,3, Gal Ofir 1,¤, Alexander Brandis 4, Tevie Mehlman 4, Philip J Kranzusch 2,3,5, Rotem Sorek 1,*
Editor: Asif Ali6
PMCID: PMC11025887  PMID: 38635746

Abstract

Sterile alpha and TIR motif-containing 1 (SARM1) is a protein involved in programmed death of injured axons. Following axon injury or a drug-induced insult, the TIR domain of SARM1 degrades the essential molecule nicotinamide adenine dinucleotide (NAD+), leading to a form of axonal death called Wallerian degeneration. Degradation of NAD+ by SARM1 is essential for the Wallerian degeneration process, but accumulating evidence suggest that other activities of SARM1, beyond the mere degradation of NAD+, may be necessary for programmed axonal death. In this study we show that the TIR domains of both human and fruit fly SARM1 produce 1′′–2′ and 1′′–3′ glycocyclic ADP-ribose (gcADPR) molecules as minor products. As previously reported, we observed that SARM1 TIR domains mostly convert NAD+ to ADPR (for human SARM1) or cADPR (in the case of SARM1 from Drosophila melanogaster). However, we now show that human and Drosophila SARM1 additionally convert ~0.1–0.5% of NAD+ into gcADPR molecules. We find that SARM1 TIR domains produce gcADPR molecules both when purified in vitro and when expressed in bacterial cells. Given that gcADPR is a second messenger involved in programmed cell death in bacteria and likely in plants, we propose that gcADPR may play a role in SARM1-induced programmed axonal death in animals.

Introduction

TIR (Toll/interleukin-1 receptor) domains are evolutionarily conserved protein domains that play key roles in innate immunity and cell-death pathways in animals, plants, and bacteria [14]. These domains frequently present catalytic activity targeting the molecule nicotinamide adenine dinucleotide (NAD+) as a substrate [3, 59]. In both plants and bacteria, TIR domains were shown to cleave NAD+ and process it into adenosine-containing molecules that act as second messenger immune signals, activating programmed cell death in response to infection. For example, some plant TIR-containing immune receptors, once they recognize effectors of plant pathogens, generate phosphoribosyl adenosine monophosphate (pRib-AMP), ADP-ribose-ATP (ADPR-ATP), or di-ADPR molecules. These molecules bind and activate a complex involving the protein EDS1, triggering a signaling cascade that leads to plant resistance and cell death [7, 8]. Other plant TIR-containing immune proteins were shown to process NAD+ into 1′′–2′ glycocyclic ADP ribose (1′′–2′ gcADPR) and 1′′–3′ gcADPR molecules [5, 10, 11]. In bacteria, TIR domain proteins in an anti-phage system called Thoeris recognize phage infection, and then process NAD+ into 1′′–3′ gcADPR. This molecule activates a protein called ThsA that leads to premature death of the infected bacterial cell prior to phage maturation [9, 10, 12]. In other bacterial immune systems such as CBASS, Pycsar and prokaryotic Argonaute systems, TIR domains serve as NAD+-depleting factors [1317]. These highly processive TIRs use their NAD+-processing capacity to eliminate NAD+ from the cell in response to phage infection, thus depleting the cell of energy and aborting phage infection [15, 1719].

In human cells, TIR domains are frequently associated with Toll-like receptors and other immune adaptor proteins [1, 20]. These TIRs are considered catalytically inactive and they transfer the immune signal via protein-protein interactions [2123]. However, there is one human TIR-domain containing protein, called sterile alpha and TIR motif-containing 1 (SARM1), in which the TIR domain is catalytically active [6]. SARM1 is a key player in a neuronal programmed axon death pathway called Wallerian degeneration, in which injured axons are degenerated in an orderly manner [2426]. Wallerian degeneration is characterized by granular disintegration of the axonal cytoskeleton, mitochondrial swelling, and axon fragmentation [27]. The Wallerian degeneration pathway was shown to depend on the activation of SARM1 [28] which, once activated, cleaves NAD+ and depletes it from the injured axon [6, 29, 30]. Indeed, cells in which SARM1 is mutated in the catalytic site do not undergo programmed axonal death following axonal insult [6].

While NAD+ depletion by SARM1 is considered a key factor of Wallerian degeneration, the precise mechanism by which SARM1 activity causes Wallerian degeneration is not yet fully understood [25, 31, 32]. For example, the Axundead mutant in Drosophila is able to prevent axon degeneration even with SARM1 activation, indicating that there are additional factors downstream to SARM1-mediated NAD+ depletion that are required for programmed axonal death [33]. Additionally, multiple studies showed that blocking Ca2+ influx into axons can prevent axonal degeneration, suggesting a connection between SARM1 and Ca2+ signaling [34, 35]. It was shown that neuronal depletion of NAD+ by factors other than SARM1 does not induce Wallerian degeneration [3638], and, accordingly, it was suggested that factors other than NAD+ depletion by SARM1 participate in orchestrating Wallerian degeneration [25, 32]. In this study, we provide evidence that the TIR domain of SARM1 is capable of generating 1′′–2′ gcADPR and 1′′–3′ gcADPR molecules. We propose that these molecules might have a role as signaling molecules in the Wallerian degeneration pathway.

Materials and methods

Bacterial strains

For the generation of cell lysates, E. coli strain BL21(DE3) (Agilent) was grown in MMB (LB supplemented with 0.1 mM MnCl2 and 5 mM MgCl2) at 37°C. Whenever applicable, media were supplemented with chloramphenicol (30 μg mL−1) or kanamycin (50 μg mL−1), to ensure the maintenance of plasmids. For protein purification, E. coli strain BL21(DE3) (Agilent) was grown in 2YT media (1.6% Bacto-tryptone, 1% yeast extract, 0.5% NaCl) at 37°C in the presence of ampicillin (100 μg mL−1) to ensure maintenance of plasmids.

Plasmid and strain construction

The human SARM1 TIR and SARM1 TIR E642A used for the cell lysates experiments were synthesized with codon optimization and cloned into a pET28 backbone by Twist Bioscience (S1 and S2 Files). The Drosophila SARM1 TIR used for the cell lysates experiments was synthesized with codon optimization by Genscript Corp and then cloned by Gibson assembly into a pACYC backbone with a Twin Strep tag fused to the N-terminus (S3 File). The E919A mutation was introduced using a KLD Enzyme Mix (NEB, no. M0554) with primers CCAGTCCTTACAATCTTCGTC and GTACATCGGGcGATCGTAGCGG (S4 File). The human and Drosophila SARM1 TIR used for in vitro reactions were codon optimized for bacterial expression and cloned from synthetic DNA fragments (Integrated DNA Technologies) by Gibson assembly into a custom pET expression vector with an N-terminal 6× His tag and an ampicillin resistance gene (S5 and S6 Files). cmTad1, AbTIRTIR, and ThsB’ were cloned similarly into pET expression vectors with an N-terminal 6×His-SUMO tag (cmTad1, AbTIRTIR) or a C-terminal 6×His tag (ThsB′) as previously reported by Yirmiya et al., 2024. The human and Drosophila SARM1 TIR used in this paper are based on UniProt accessions Q6SZW1 and Q6IDD9, respectively. Only the TIR domain was used.

SARM1 TIR domains expression and lysate preparation for LC-MS analyses

Overnight cultures of bacteria containing WT or mutated SARM1 TIR domains were diluted 1:100 in 200 mL MMB and incubated at 37°C with shaking (200 r.p.m.) until reaching OD600 of 0.3. At this point, IPTG was added to a concentration of 1 mM and the temperature was dropped to 30°C for an additional 4 hours. 50 mL samples were collected and centrifuged at 4°C for 10 min to pellet the cells. The supernatant was discarded and the tube was frozen at −80°C. To extract the metabolites, 600 μl of 100 mM Na phosphate buffer at pH 8 was added to each pellet. The thawed samples were transferred to a FastPrep Lysing Matrix B 2 mL tube (MP Biomedicals catalogue no. 116911100) and lysed using FastPrep bead beater for 40 s at 6 m s−1 in two rounds. Tubes were then centrifuged at 4°C for 15 min at 15,000g. Supernatant was transferred to Amicon Ultra-0.5 Centrifugal Filter Unit 3 kDa (Merck Millipore catalogue no. UFC500396) and centrifuged for 45 min at 4°C at 12,000g. Where specified, filtrate was incubated with cmTad1 as previously described in Leavitt et al., 2022. Filtrate was taken and used for ThsA activity assays and for liquid chromatography mass spectrometry (LC-MS) analyses.

In vitro production and purification of gcADPR molecules

1′′–2′ and 1′′–3′ gcADPR were produced and purified as previously described in detail [39]. In brief, purified recombinant AbTIRTIR and ThsB′ were used to set up reactions with NAD+. Reactions were carried out at room temperature for 24–48 hours before boiling at 95°C for 10–15 minutes. Samples were clarified by centrifugation (13,500 g, 20 min), passed through a 10 kDa filter, and cmTad1 was added to the filtrate. Mixtures were incubated at RT for 1 h to allow complex formation before washing by successive concentration and dilution in a 10 kDa concentration unit, first with PBS, then with water. Complexes were concentrated to >3 mM before boiling at 95°C for 10 minutes, centrifugation (13,500 g, 20 min), and filtering through a 3 kDa filter. For long-term storage and shipment, samples were vacuum dehydrated and kept at –20°C.

ThsA NADase activity assay

The NADase reaction was performed in black 96-well half area plates (Corning, 3694). In each microwell, ThsA protein which was purified as previously described (Ofir et al., 2021), was added to cell lysate or to a positive control of 100 mM sodium phosphate buffer pH 8 supplemented with 1′′–3′ gcADPR standards. ThsA was added to a final concentration of 100 nM protein in a 50 μl final volume reaction. Five microlitres of 5 mM nicotinamide 1,N6 -ethenoadenine dinucleotide (εNAD, Sigma,N2630) solution was added to each well immediately before the beginning of measurements and mixed by pipetting to reach a concentration of 500 μM in the 50 μl final reaction volume. Plates were incubated inside a Tecan Infinite M200 plate reader at 25°C, and measurements were taken every 1 min at 300 nm excitation wavelength and 410 nm emission wavelength. Reaction rate was calculated from the linear part of the initial reaction.

Quantification of metabolites by LC-MS/MS

Quantification of metabolites in cell lysates or in the in vitro reactions was carried out using an Acquity I-class UPLC system coupled to Xevo TQ-S triple quadrupole mass spectrometer (both Waters, US). The UPLC was performed using an Atlantis Premier BEH C18 AX column with the dimension of 2.1 × 100 mm and particle size of 1.7 μm (Waters). Mobile phase A was 20 mM ammonium formate at pH 3 and acetonitrile was mobile phase B. The flow rate was kept at 300 μl min−1 consisting of a 2 min hold at 2% B, followed by linear gradient increase to 100% B during 5 min. The column temperature was set at 25°C and an injection volume of 1 μl. An electrospray ionization interface was used as ionization source. Analysis was performed in positive ionization mode. Metabolites were analyzed using multiple-reaction monitoring with argon as the collision gas, and detected based on retention times and MS/MS parameters of chemical standards (S1 Fig). Quantification was made using standard curve in 0–1 mM concentration range. 15N5-adenosine 5′-monophosphate (Sigma) was added to standards and samples as internal standard (0.5 μM). TargetLynx (Waters) was used for data analysis.

SARM1 TIR domain purification for in vitro reactions

Human and Drosophila SARM1 TIR expression plasmids were transformed into E. coli BL21(DE3) (Agilent). Bacterial colonies were grown on LB agar plates, and 15 mL of 2YT media starter cultures were grown overnight at 37°C with 230 rpm shaking from three picked colonies. 1L of 2YT expression culture supplemented with 10 mM nicotinamide was seeded with 15 mL starter culture and grown at 37°C with 230 rpm shaking to an OD600 of 2.5 before expression induction with 0.5 mM IPTG. The temperature was then lowered to 16°C, and cultures were harvested by centrifugation after 16–20 h. Cell pellets from 2 L of culture were resuspended in 120 mL lysis buffer (20 mM HEPES-KOH pH 7.5, 400 mM NaCl, 10% glycerol, 30 mM imidazole, 1 mM DTT), lysed by sonication, and clarified by centrifugation at 25,000g for 20 min. Lysate was passed over a gravity column of 8 mL of Ni-NTA resin (Qiagen), washed with 70 mL wash buffer (20 mM HEPES-KOH pH 7.5, 1M NaCl, 10% glycerol, 30 mM imidazole, 1 mM DTT), and eluted with 20 mL of lysis buffer supplemented to 300 mM imidazole. Eluate was dialyzed against storage buffer (20 mM HEPES-KOH pH 7.5, 250 mM KCl, 1 mM TCEP) overnight at 4°C, concentrated to >4 mg/mL, flash frozen, and stored at −80°C.

Protein purity was assayed by SDS-PAGE. ~2 μg purified protein was separated on a 15% bis-acrylamide SDS gel (S2 Fig), and sizes were estimated using Blue Protein Standard (New England Biolabs). N-terminally 6×His-tagged fusions of human and Drosophila SARM1 TIR have an expected molecular weight of 19.2 kDa.

In vitro SARM1 TIR domain reactions and sample preparation

Purified human and Drosophila SARM1 TIR recombinant proteins were used to set up 0.3 mL reactions (10 μM protein, 1 mM NAD+, 50 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM TCEP). Reactions were carried out at 37°C for 16 h, stopped by filtering through a 3 kDa filter (Amicon), and stored at −20°C.

Results

This study was initiated upon the surprising observation that lysates from cells expressing the TIR domain of SARM1 are able to activate the bacterial ThsA protein (Fig 1A, 1B and S1 Table). ThsA is an anti-phage enzyme specifically activated by the molecule 1′′–3′ gcADPR, but not by the canonical cADPR, ADPR, or other ADPR derivatives [5, 10, 12], and we therefore suspected that SARM1 activity might generate 1′′–3′ gcADPR. We cloned the TIR domain of SARM1 from both human and Drosophila melanogaster (fruit fly) and overexpressed these TIR domains within Escherichia coli cells. We then extracted cell lysates and filtered them through 3 kDa filters to retain only small molecules. The in vitro activity of ThsA was triggered by filtered lysates of both human and D. melanogaster SARM1 TIRs (Fig 1B). Lysates from bacteria expressing SARM1 TIR with mutations in the known catalytic glutamic acid residue did not induce the in vitro activity of ThsA (Fig 1B), suggesting that the enzymatic activity of SARM1 TIR is essential for producing 1′′–3′ gcADPR. In agreement with the well documented NADase activity of SARM1, cells expressing the SARM1 TIR domain were depleted of NAD+ (Fig 1C).

Fig 1. Detection of 1′′–3′ gcADPR in lysates of bacteria expressing the SARM1 TIR domain.

Fig 1

(a) Schematic representation of the experiment. Filtered lysates of cells expressing SARM1 TIR or SARM1 TIR active site mutants were tested for activation of the ThsA protein. NADase activity of ThsA was measured using a nicotinamide 1,N6-ethenoadenine dinucleotide (εNAD) cleavage fluorescence assay. (b) Activity of purified ThsA protein from B. cereus, incubated with increasing concentration of 1′′–3′ gcADPR as well as with lysates derived from bacteria that express the SARM1 TIR domain from human and D. melanogaster. Data are also shown for lysates from bacteria expressing the SARM1 TIR domains with catalytic site mutations, as well as lysates that were pre-incubated with Tad1. Bars represent the mean of three independent replicates, with individual data points overlaid. Asterisks indicate a statistically significant difference (one-way ANOVA followed by pairwise multiple comparison analysis according to Tukey’s honest significant difference criterion, P < 0.05). (c) LC-MS analysis showing concentrations of NAD+ in cell lysates extracted from E. coli expressing human and Drosophila SARM1 TIR domains. Control cells in this experiment express SARM1 TIR domains with catalytic site mutations. Bar graphs represent the average of three independent replicates, with individual data points overlaid. Asterisk marks statistically significant increase (Student’s t-test, two-sided, P <0.05). (d) LC-MS analysis showing concentrations of 1′′–3′ gcADPR in cell lysates extracted from E. coli expressing human and Drosophila SARM1 TIR domains. The cells used in this experiment are as in panel c. Bar graphs represent the average of three independent replicates, with individual data points overlaid. Asterisk marks statistically significant decrease (Student’s t-test, two-sided, P <0.05).

To further examine whether the molecule present within SARM1 TIR-expressing cells was indeed gcADPR, we exposed the filtered cell lysates to Tad1, a phage-derived protein that is known to specifically bind and sequester 1′′–3′ gcADPR and 1′′–2′ gcADPR molecules, but not cADPR or ADPR [12]. Lysates from SARM1 TIR-expressing cells lost their ability to activate ThsA if pre-incubated with Tad1, suggesting that Tad1 had sequestered the 1′′–3′ gcADPR molecule from these lysates (Fig 1B).

To substantiate that SARM1 expression produces 1′′–3′ gcADPR, we subjected filtered cell lysates from E. coli cells overexpressing the human and Drosophila SARM1 TIR domains to targeted mass spectrometry analysis. Lysates from cells expressing both human and Drosophila SARM1 TIR domains showed a clear presence of 1′′–3′ gcADPR, while lysates of bacteria expressing catalytic site mutations in these domains did not (Fig 1D). These results suggest that when expressed in bacteria, the NADase activity of the SARM1 TIR domain generates 1′′–3′ gcADPR.

To test the extent to which SARM1 TIR domains produce 1′′–3′ gcADPR, we purified the TIR domains of SARM1 from human and Drosophila and incubated the purified proteins with NAD+. As expected from previous studies [6, 40, 41], SARM1 TIR domains consumed NAD+ efficiently. The NAD+ molecules were largely converted into ADPR (in the case of human SARM1) or into cADPR (for Drosophila SARM1), as previously shown for these two proteins [6] (Fig 2). However, we were also able to detect the accumulation of 1′′–3′ gcADPR as well as the molecule 1′′–2′ gcADPR in both human and Drosophila samples. In vitro, the recombinant Drosophila SARM1 TIR produces about one 1′′–3′ gcADPR molecule for every 300 cADPR molecules it generates, and about 1:1000 1′′–2′ gcADPR:cADPR molecules. The human SARM1 TIR seems to generate roughly 1 gcADPR molecule for every 200 conversions in vitro.

Fig 2. LC-MS analysis of the products of in vitro reaction with purified SARM1 TIR domains.

Fig 2

Concentrations of molecules in filtered in vitro reactions containing purified human or D. melanogaster SARM1 TIR domains. 10 μM of protein was incubated with ~1 mM NAD+ for 16 hours. Controls in this experiment had no protein added to the reaction. Bar graphs represent the average of three independent replicates, with individual data points overlaid. Asterisk marks statistically significant difference (Student’s t-test, two-sided, P <0.05).

Discussion

Our results demonstrate that the TIR domain of SARM1 generates 1′′–2′ and 1′′–3′ gcADPR molecules as minor products when expressed in or purified from bacteria. Generation of gcADPR molecules appears to be a conserved feature of SARM1 TIR activity, as this activity was observed for both human and insect SARM1 TIR domains. Although the majority of NAD+ processing by the SARM1 TIR generates ADPR and cADPR molecules as products, gcADPR molecules may accumulate in biologically meaningful concentrations in cells undergoing Wallerian degeneration. Human cells typically contain 0.2–0.5 mM of NAD+ molecules [42], and if 0.1–0.5% of this NAD+ is converted by SARM1 into gcADPR, this activity could generate high nanomolar to low micromolar levels of gcADPR in axons. We postulate that this molecule may function as a second messenger, in which case it would bind a receiver protein to trigger downstream activities contributing to programmed axonal death. Notably, intracellular second messenger signaling molecules, and specifically those involved in immunity and/or the activation of cell death, typically activate their cognate receptor in high nanomolar to low micromolar concentrations [13, 15, 43]. An alternative explanation for our observations is that gcADPR production by SARM1 may be a nonfunctional byproduct of highly processive NADase activity of the SARM1 TIR domain. Notably, we observed production of gcADPR when SARM1 TIR domains were overexpressed in bacterial cells, and it is possible that the full length SARM1 protein does not generate these molecules when expressed at physiological levels in the native animal cells.

In bacteria, 1′′–3′ gcADPR molecules are produced by TIR domains in response to phage infection. These molecules activate ThsA by specifically binding a domain called SLOG found at the C-terminus of ThsA. Binding of 1′′–3′ gcADPR to the SLOG domain results in conformational changes that alter the oligomeric state of ThsA to activate the protein [9]. SLOG-like domains are also found in human proteins, specifically in calcium channels from the TRPM family where they were shown to bind ADPR derivatives [44, 45]. Given that activation of Ca2+ influx has been linked to Wallerian degeneration downstream of SARM1 activity [34], it is worth understanding if calcium channel receptors could potentially respond to gcADPR produced by SARM1.

Although the NADase activity of SARM1 is well established as essential for Wallerian degeneration, the mechanism linking NAD+ depletion to axonal degeneration is not yet entirely clear [25, 31, 32]. Indeed, previous studies have suggested that additional factors acting downstream to NAD+ depletion by SARM1 may be necessary for the orderly death of injured axons [25, 33]. The gcADPR molecules revealed in this study as minor products of SARM1 TIR domains might be related to additional processes that could operate downstream of SARM1. Whether these molecules indeed accumulate in axons during Wallerian degeneration, and whether they have a biological function in axonal death, remains to be determined by future studies.

Supporting information

S1 Fig. Standards of NAD+, ADPR, cADPR and gcADPR molecules as measured via targeted mass spectrometry.

Extracted mass chromatograms of specified ions, detected in a sample containing equal concentration of each standard, demonstrating the difference in retention times. Peak height is normalized to the highest peak in frame.

(TIF)

pone.0302251.s001.tif (495.2KB, tif)
S2 Fig. Protein purification of human and Drosophila SARM1 TIR proteins.

~2 μg purified protein was separated on a 15% bis-acrylamide SDS gel and sizes were estimated using protein standard. N-terminally 6×His-tagged fusions of human and Drosophila SARM1 TIR have an expected molecular weight of 19 kDa (corresponding bands marked by asterisk).

(TIF)

pone.0302251.s002.tif (273.8KB, tif)
S1 Table. Raw data for Figs 1 and 2 (included as an excel sheet).

(XLSX)

pone.0302251.s003.xlsx (13.7KB, xlsx)
S1 File. Plasmid map.

(TXT)

pone.0302251.s004.txt (10KB, txt)
S2 File. Plasmid map.

(TXT)

pone.0302251.s005.txt (10KB, txt)
S3 File. Plasmid map.

(TXT)

pone.0302251.s006.txt (14KB, txt)
S4 File. Plasmid map.

(TXT)

pone.0302251.s007.txt (13.8KB, txt)
S5 File. Plasmid map.

(TXT)

pone.0302251.s008.txt (9.9KB, txt)
S6 File. Plasmid map.

(TXT)

pone.0302251.s009.txt (9.9KB, txt)
S7 File. Raw gel images.

(PDF)

pone.0302251.s010.pdf (561.6KB, pdf)

Acknowledgments

We thank A. Yaron, O. Abraham, N. Pursotham, and S. Hobbs for fruitful discussions on SARM1 activity and biochemical analysis of gcADPR signaling, as well as the Sorek and Kranzusch lab members for comments on the manuscript.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

We thank A. Yaron, O. Abraham, N. Pursotham, and S. Hobbs for fruitful discussions on SARM1 activity and biochemical analysis of gcADPR signaling, as well as the Sorek and Kranzusch lab members for comments on the manuscript. R.S. was supported, in part, by the European Research Council (grant no. ERC-AdG GA 101018520), Israel Science Foundation (MAPATS Grant 2720/22), the Deutsche Forschungsgemeinschaft (SPP 2330, Grant 464312965), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, Dr. Barry Sherman Institute for Medicinal Chemistry, Miel de Botton, the Andre Deloro Prize, and the Knell Family Center for Microbiology. P.J.K. was supported, in part, by the Pew Biomedical Scholars program and The Mathers Foundation. G.O. was supported by the SAERI doctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998;95: 588–593. doi: 10.1073/pnas.95.2.588 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Aliprantis AO, Yang R-B, Mark MR, Suggett S, Devaux B, Radolf JD, et al. Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2. Science. 1999;285: 736–739. doi: 10.1126/science.285.5428.736 [DOI] [PubMed] [Google Scholar]
  • 3.Essuman K, Milbrandt J, Dangl JL, Nishimura MT. Shared TIR enzymatic functions regulate cell death and immunity across the tree of life. Science. 2022. pp. 0–12. doi: 10.1126/science.abo0001 [DOI] [PubMed] [Google Scholar]
  • 4.Nimma S, Gu W, Maruta N, Li Y, Pan M, Saikot FK, et al. Structural Evolution of TIR-Domain Signalosomes. Front. Immunol. 2021;12: 1–10. doi: 10.3389/fimmu.2021.784484 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bayless AM, Chen S, Ogden SC, Xu X, Sidda JD, Manik MK, et al. Plant and prokaryotic TIR domains generate distinct cyclic ADPR NADase products. Sci Adv. 2023;9: eade8487. doi: 10.1126/sciadv.ade8487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration. Neuron. 2017;93: 1334–1343.e5. doi: 10.1016/j.neuron.2017.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Huang S, Jia A, Song W, Hessler G, Meng Y, Sun Y, et al. Identification and receptor mechanism of TIR-catalyzed small molecules in plant immunity. Science. 2022;377: eabq3297. doi: 10.1126/science.abq3297 [DOI] [PubMed] [Google Scholar]
  • 8.Jia A, Huang S, Song W, Wang J, Meng Y, Sun Y, et al. TIR-catalyzed ADP-ribosylation reactions produce signaling molecules for plant immunity. Science. 2022;377: eabq8180. doi: 10.1126/science.abq8180 [DOI] [PubMed] [Google Scholar]
  • 9.Ofir G, Herbst E, Baroz M, Cohen D, Millman A, Doron S, et al. Antiviral activity of bacterial TIR domains via signaling molecules that trigger cell death. Nature. 2021;600: 116–120. doi: 10.1101/2021.01.06.425286 [DOI] [PubMed] [Google Scholar]
  • 10.Manik MK, Shi Y, Li S, Zaydman MA, Damaraju N, Eastman S, et al. Cyclic ADP ribose isomers: Production, chemical structures, and immune signaling. Science. 2022;377: eadc8969. doi: 10.1126/science.adc8969 [DOI] [PubMed] [Google Scholar]
  • 11.Wan L, Essuman K, Anderson RG, Sasaki Y, Monteiro F, Chung EH, et al. TIR domains of plant immune receptors are NAD+-cleaving enzymes that promote cell death. Science. 2019;365: 799–803. doi: 10.1126/science.aax1771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Leavitt A, Yirmiya E, Amitai G, Lu A, Garb J, Herbst E, et al. Viruses inhibit TIR gcADPR signalling to overcome bacterial defence. Nature. 2022;611: 326–331. doi: 10.1038/s41586-022-05375-9 [DOI] [PubMed] [Google Scholar]
  • 13.Cohen D, Melamed S, Millman A, Shulman G, Oppenheimer-Shaanan Y, Kacen A, et al. Cyclic GMP–AMP signalling protects bacteria against viral infection. Nature. 2019;574: 691–695. doi: 10.1038/s41586-019-1605-5 [DOI] [PubMed] [Google Scholar]
  • 14.Millman A, Melamed S, Amitai G, Sorek R. Diversity and classification of cyclicoligonucleotide-based anti-phage signalling systems. Nat Microbiol. 2020;5: 1608–1615. doi: 10.1038/s41564-020-0777-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Tal N, Morehouse BR, Millman A, Stokar-Avihail A, Avraham C, Fedorenko T, et al. Cyclic CMP and cyclic UMP mediate bacterial immunity against phages. Cell. 2021;184: 5728–5739.e16. doi: 10.1016/j.cell.2021.09.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ni D, Lu X, Stahlberg H, Ekundayo B. Activation mechanism of a short argonaute-TIR prokaryotic immune system. Sci Adv. 2023;9: eadh9002. doi: 10.1126/sciadv.adh9002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Koopal B, Potocnik A, Mutte SK, Vervoort JJM, Brouns SJJ, Swarts DC. Article Short prokaryotic Argonaute systems trigger cell death upon detection of invading DNA Graphical abstract ll ll Short prokaryotic Argonaute systems trigger cell death upon detection of invading DNA. Cell. 2022;185: 1471–1486.e19. doi: 10.1016/j.cell.2022.03.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Morehouse BR, Govande AA, Millman A, Keszei AFA, Lowey B, Ofir G, et al. STING cyclic dinucleotide sensing originated in bacteria. Nature. 2020;586: 429–433. doi: 10.1038/s41586-020-2719-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Morehouse BR, Yip MCJ, Keszei AFA, McNamara-Bordewick NK, Shao S, Kranzusch PJ. Cryo-EM structure of an active bacterial TIR–STING filament complex. Nature. 2022;608: 803–807. doi: 10.1038/s41586-022-04999-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Neill LAJO Bowie AG. The family of five: TIR-domain- containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7: 353–364. doi: 10.1038/nri2079 [DOI] [PubMed] [Google Scholar]
  • 21.Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. Cell. 2020;180: 1044–1066. doi: 10.1016/j.cell.2020.02.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000;408: 111–115. doi: 10.1038/35040600 [DOI] [PubMed] [Google Scholar]
  • 23.Yang R, Mark M, Gray A, Al. E. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 1998;395: 284–288. [DOI] [PubMed] [Google Scholar]
  • 24.Figley MD, DiAntonio A. The SARM1 axon degeneration pathway: control of the NAD+ metabolome regulates axon survival in health and disease. Curr Opin Neurobiol. 2020;63: 59–66. doi: 10.1016/j.conb.2020.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Coleman MP, Höke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat Rev Neurosci. 2020;21: 183–196. doi: 10.1038/s41583-020-0269-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337: 481–484. doi: 10.1126/science.1223899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Waller A. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. Philos Trans R Soc London. 1850;140: 423–429. doi: 10.1098/rstl.1850.0021 [DOI] [Google Scholar]
  • 28.Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science. 2015;348: 453–457. doi: 10.1126/science.1258366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Figley MD, Gu W, Nanson JD, Shi Y, Sasaki Y, Cunnea K, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109: 1118–1136.e11. doi: 10.1016/j.neuron.2021.02.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Geisler S, Milbrandt J, Diantonio A, Geisler S, Doan RA, Cheng GC, et al. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program. JCI Insight. 2019;4: e129920. doi: 10.1172/jci.insight.129920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Loring HS, Thompson PR. Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases. Cell Chem Biol. 2020;27: 1–13. doi: 10.1016/j.chembiol.2019.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Eastman S, Bayless A, Guo M. The Nucleotide Revolution: Immunity at the Intersection of Toll/Interleukin-1 Receptor Domains, Nucleotides, and Ca 2+. Mol Plant-Microbe Interact. 2022;35: 964–976. doi: 10.1094/MPMI-06-22-0132-CR [DOI] [PubMed] [Google Scholar]
  • 33.Neukomm LJ, Burdett TC, Seeds AM, Hampel S, Coutinho-Budd JC, Farley JE, et al. Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly. Neuron. 2017;95: 78–91.e5. doi: 10.1016/j.neuron.2017.06.031 [DOI] [PubMed] [Google Scholar]
  • 34.Li Y, Pazyra-Murphy MF, Avizonis D, Russo MT, Tang S, Chen CY, et al. Sarm1 activation produces cADPR to increase intra-axonal Ca++ and promote axon degeneration in PIPN. J Cell Biol. 2022;221: e202106080. doi: 10.1083/jcb.202106080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ko KW, Devault L, Sasaki Y, Milbrandt J, Diantonio A. Live imaging reveals the cellular events downstream of SARM1 activation. Davis GW, Pfeffer SR, editors. Elife. 2021;10: e71148. doi: 10.7554/eLife.71148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Stefano M Di, Orsomando G, Mori V, Gilley J, Brown R, Janeckova L, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015; 731–742. doi: 10.1038/cdd.2014.164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Liu H, Smith CB, Schmidt MS, Cambronne XA, Cohen MS, Migaud ME. Pharmacological bypass of NAD + salvage pathway protects neurons from chemotherapy- induced degeneration. Proc Natl Acad USA. 2018;115: 10654–10659. doi: 10.1073/pnas.1809392115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Clark DE, Waszkowycz B, Wong M, Lockey PM, Adalbert R, Gilley J, et al. Bioorganic & Medicinal Chemistry Letters Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies. Bioorg Med Chem Lett. 2016;26: 2920–2926. doi: 10.1016/j.bmcl.2016.04.039 [DOI] [PubMed] [Google Scholar]
  • 39.Yirmiya E, Leavitt A, Lu A, Avraham C, Osterman I, Garb J, et al. Phages overcome bacterial immunity via diverse anti-defense proteins. Nature. 2024;625: 352–359. doi: 10.1038/s41586-023-06869-w [DOI] [PubMed] [Google Scholar]
  • 40.Horsefield S, Burdett H, Zhang X, Manik MK, Shi Y, Chen J, et al. NAD+ cleavage activity by animal and plant TIR domains in cell death pathways. Science. 2019;365: 793–799. doi: 10.1126/science.aax1911 [DOI] [PubMed] [Google Scholar]
  • 41.Essuman K, Summers DW, Sasaki Y, Mao X, Yim AKY, DiAntonio A, et al. TIR Domain Proteins Are an Ancient Family of NAD+-Consuming Enzymes. Curr Biol. 2018;28: 421–430.e4. doi: 10.1016/j.cub.2017.12.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cantó C, Menzies KJ, Auwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22: 31–53. doi: 10.1016/j.cmet.2015.05.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Carozza JA, Böhnert V, Nguyen KC, Skariah G, Shaw KE, Brown JA, et al. Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat cancer. 2020;1: 184–196. doi: 10.1038/s43018-020-0028-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Huang Y, Winkler PA, Sun W, Lü W, Du J. Architecture of the TRPM2 channel and its activation mechanism by ADP-ribose and calcium. Nature. 2018;562: 145–163. doi: 10.1038/s41586-018-0558-4 [DOI] [PubMed] [Google Scholar]
  • 45.Huang Y, Fliegert R, Guse AH, Lü W, Du J. A structural overview of the ion channels of the TRPM family. Cell Calcium. 2020;85: 102111. doi: 10.1016/j.ceca.2019.102111 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Asif Ali

6 Feb 2024

PONE-D-23-31863The SARM1 TIR domain produces glycocyclic ADPR molecules as minor productsPLOS ONE

Dear Dr. Garb,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Mar 22 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Asif Ali

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

4. Thank you for stating the following financial disclosure: 

   "We thank A. Yaron, O. Abraham, N. Pursotham, and S. Hobbs for fruitful discussions on SARM1 activity and biochemical analysis of gcADPR signaling, as well as the Sorek and Kranzusch lab members for comments on the manuscript. R.S. was supported, in part, by the European Research Council (grant no. ERC-AdG GA 101018520), Israel Science Foundation (MAPATS Grant 2720/22), the Deutsche Forschungsgemeinschaft (SPP 2330, Grant 464312965), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, Dr. Barry Sherman Institute for Medicinal Chemistry, Miel de Botton, the Andre Deloro Prize, and the Knell Family Center for Microbiology. P.J.K. was supported, in part, by the Pew Biomedical Scholars program and The Mathers Foundation. G.O. was supported by the SAERI doctoral fellowship."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating the following in the Competing Interests section: 

   "P.J.K, R.S, G.A and A.L. are inventors of a patent application related to the production and utility of gcADPR. R.S. is a scientific cofounder and advisor of BiomX and Ecophage. The rest of the authors declare no conflict of interest."

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. 

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

6. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

The manuscript titled "The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products" by Garb et al. presents significant findings related to gcADPR molecules during Wallerian degeneration by the SARM1 TIR domain. Reviewer #1 highlights the need for statistical details, raw data in supplementary materials, and an exploration of evolutionary differences between Drosophila and human SARM1 TIR domains. Reviewer #2 expresses concern about the lack of evidence regarding the role of gcADPR molecules in inducing cell death, seeks an explanation for the Drosophila's higher catalytic activity, and recommends including stastical significance values for figures. Addressing these comments will enhance the manuscript's rigor and suitability for publication.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Review Comments

The manuscript "The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products" by Garb et al. is a good discovery about gcADPR molecules during Wallerian degeneration by SARM1 TIR domain. This research article provides importance of small molecules during stress conditions. This manuscript is of interest to the neurobiology and human biology researchers, as well as different biology researchers and I expect that the article will be well-cited. I have the following minor comments to consider.

1. Authors add statistical details in their figure’s legend and statistical section in materials and methods.

2. Authors should provide raw data of figures in supplementary with details?

3. In both figures, the Drosophila SARM1 TIR domain is more catalytically active than the human SARM1I, therefore I recommend that the authors consider your results from an evolutionary standpoint as well. Is there any difference in protein sequence in the Drosophila and human catalytic sites? Would like to give some insights about that in manuscript discussions?

Reviewer #2: The manuscript titled “The SARM1 TIR domain produces glycolytic ADPR molecules as minor products” discusses the generation of 1''-2 and 1''-3 glycolytic ribose molecules as subordinate products of TIR domains in both human and Drosophila SARM1. The authors, through well-defined experiments, have preliminarily concluded that these molecules are minor reaction products, yet they also suggest that these byproducts may play a role in SARM1-induced programmed axonal death in animals. However, they have not provided evidence for the latter part. Despite this, the novel findings are noteworthy and could be considered for acceptance once the following concerns are addressed.

1. In an invitro setting, it is unclear whether the 1”-2 and 1”-3 gcADPR molecules (in concentrations ranging from high nanomolar to low micromolar) alone or in combination with ADPR or cADPR induce cell death of cultured axons.

2. The inclusion of a mutated TIR domain protein in the mass spectrometry analysis presented in Figure 2 would enhance the study.

3. An explanation for the increased activity of the Drosophila TIR domain compared to the human TIR domain would be informative.

4. Please include the significance values of the figures.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Pawan Kumar

Reviewer #2: Yes: Suvranil Ghosh

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <

Attachment

Submitted filename: PlosOne Review TIR domain SARM1.docx

pone.0302251.s011.docx (13.8KB, docx)
PLoS One. 2024 Apr 18;19(4):e0302251. doi: 10.1371/journal.pone.0302251.r002

Author response to Decision Letter 0


19 Mar 2024

A response to reviewers letter is included in this submission.

We thank the referees for their thoughtful comments and suggestions. Our point-to-point response to each of the referees’ comments is detailed below.

Reviewer #1: Review Comments

The manuscript "The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products" by Garb et al. is a good discovery about gcADPR molecules during Wallerian degeneration by SARM1 TIR domain. This research article provides importance of small molecules during stress conditions. This manuscript is of interest to the neurobiology and human biology researchers, as well as different biology researchers and I expect that the article will be well-cited.

Answer: Thank you for acknowledging the importance of our study!

I have the following minor comments to consider.

1. Authors add statistical details in their figure’s legend and statistical section in materials and methods.

Answer: We thank the reviewer for this valuable comment. We now added statistical details to figures, and explain the statistical analyses in the figure legends.

2. Authors should provide raw data of figures in supplementary with details?

Answer: We thank the reviewer for this comment. We now included the raw data for figures 1 and 2 in a new Supplementary Table S1.

3. In both figures, the Drosophila SARM1 TIR domain is more catalytically active than the human SARM1I, therefore I recommend that the authors consider your results from an evolutionary standpoint as well. Is there any difference in protein sequence in the Drosophila and human catalytic sites? Would like to give some insights about that in manuscript discussions?

Answer: We thank the reviewer for this comment. We want to emphasize that the proteins were tested in conditions other than their natural conditions in neuronal cells – we either expressed them in bacteria (Figure 1B, 1C, 1D) or in vitro (Figure 2). For this reason, we would caution against interpretations regarding different enzymatic rates between the human and Drosophila SARM1 TIRs, due to the non-native environment. To clarify this point, we modified the Discussion text and it now reads: “Notably, we observed production of gcADPR when SARM1 TIR domains were overexpressed in bacterial cells, and it is possible that the full length SARM1 protein does not generate these molecules when expressed at physiological levels in the native animal cells.”

Reviewer #2:

The manuscript titled “The SARM1 TIR domain produces glycolytic ADPR molecules as minor products” discusses the generation of 1''-2 and 1''-3 glycolytic ribose molecules as subordinate products of TIR domains in both human and Drosophila SARM1. The authors, through well-defined experiments, have preliminarily concluded that these molecules are minor reaction products, yet they also suggest that these byproducts may play a role in SARM1-induced programmed axonal death in animals. However, they have not provided evidence for the latter part. Despite this, the novel findings are noteworthy and could be considered for acceptance once the following concerns are addressed.

Answer: We thank the reviewer for acknowledging the novelty of our findings!

1. In an invitro setting, it is unclear whether the 1”-2 and 1”-3 gcADPR molecules (in concentrations ranging from high nanomolar to low micromolar) alone or in combination with ADPR or cADPR induce cell death of cultured axons.

Answer: as indicated by the reviewer in their summary above, in this study we did not test whether the molecules produced by SARM1 affect cell death in axons. We hope that our discoveries will prompt neurobiologists to examine this possibility, and hence our motivation in publishing the current manuscript. To make this point clear to the reader, our text in the Discussion section reads: “The gcADPR molecules revealed in this study as minor products of SARM1 TIR domains might be related to additional processes that could operate downstream of SARM1. Whether these molecules indeed accumulate in axons during Wallerian degeneration, and whether they have a biological function in axonal death, remains to be determined by future studies.”

2. The inclusion of a mutated TIR domain protein in the mass spectrometry analysis presented in Figure 2 would enhance the study.

Answer: We thank the reviewer for this comment, but we believe we addressed these mutations already in Figure 1. We performed our experiments including controls for active-site mutations when the SARM1 TIR was expressed in bacterial cells (Figure 1). The mutations included substitution of the active site glutamate in both the human and Drosophila SARM1 TIR, and in both cases the enzymatic activity was clearly and completely eliminated (Figure 1B, 1C, 1D). We feel that these mutations are already very convincing.

3. An explanation for the increased activity of the Drosophila TIR domain compared to the human TIR domain would be informative.

Answer: We thank the reviewer for this comment. We want to emphasize that the proteins were tested in conditions other than their natural conditions in human neuronal cells – we either expressed them in bacteria (Figure 1B, 1C, 1D) or in vitro (Figure 2). For this reason, we would caution against interpretations regarding different enzymatic rates between the human and Drosophila SARM1 TIRs, due to the non-native environment. To clarify this point, we modified the Discussion text and it now reads: “Notably, we observed production of gcADPR when SARM1 TIR domains were overexpressed in bacterial cells, and it is possible that the full length SARM1 protein does not generate these molecules when expressed at physiological levels in the native animal cells.”

4. Please include the significance values of the figures.

Answer: We thank the reviewer for this valuable comment. We have added statistical details to figures and explain the statistical analyses in the revised figure legends.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0302251.s012.docx (19.5KB, docx)

Decision Letter 1

Asif Ali

1 Apr 2024

The SARM1 TIR domain produces glycocyclic ADPR molecules as minor products

PONE-D-23-31863R1

Dear Dr. Garb,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Asif Ali

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Asif Ali

7 Apr 2024

PONE-D-23-31863R1

PLOS ONE

Dear Dr. Garb,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Asif Ali

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Standards of NAD+, ADPR, cADPR and gcADPR molecules as measured via targeted mass spectrometry.

    Extracted mass chromatograms of specified ions, detected in a sample containing equal concentration of each standard, demonstrating the difference in retention times. Peak height is normalized to the highest peak in frame.

    (TIF)

    pone.0302251.s001.tif (495.2KB, tif)
    S2 Fig. Protein purification of human and Drosophila SARM1 TIR proteins.

    ~2 μg purified protein was separated on a 15% bis-acrylamide SDS gel and sizes were estimated using protein standard. N-terminally 6×His-tagged fusions of human and Drosophila SARM1 TIR have an expected molecular weight of 19 kDa (corresponding bands marked by asterisk).

    (TIF)

    pone.0302251.s002.tif (273.8KB, tif)
    S1 Table. Raw data for Figs 1 and 2 (included as an excel sheet).

    (XLSX)

    pone.0302251.s003.xlsx (13.7KB, xlsx)
    S1 File. Plasmid map.

    (TXT)

    pone.0302251.s004.txt (10KB, txt)
    S2 File. Plasmid map.

    (TXT)

    pone.0302251.s005.txt (10KB, txt)
    S3 File. Plasmid map.

    (TXT)

    pone.0302251.s006.txt (14KB, txt)
    S4 File. Plasmid map.

    (TXT)

    pone.0302251.s007.txt (13.8KB, txt)
    S5 File. Plasmid map.

    (TXT)

    pone.0302251.s008.txt (9.9KB, txt)
    S6 File. Plasmid map.

    (TXT)

    pone.0302251.s009.txt (9.9KB, txt)
    S7 File. Raw gel images.

    (PDF)

    pone.0302251.s010.pdf (561.6KB, pdf)
    Attachment

    Submitted filename: PlosOne Review TIR domain SARM1.docx

    pone.0302251.s011.docx (13.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0302251.s012.docx (19.5KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES